Disc Medicine Inc
IRON79.720USD
+1.390+1.77%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
2.79BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Disc Medicine Inc Unternehmen
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Disc Medicine Inc Informationen
BörsenkürzelIRON
Name des UnternehmensDisc Medicine Inc
IPO-datumAug 12, 2020
CEOQuisel (John D)
Anzahl der mitarbeiter84
WertpapierartOrdinary Share
GeschäftsjahresendeAug 12
Addresse321 Arsenal Street, Suite 101
StadtWATERTOWN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02472
Telefon16176749274
Websitehttps://www.discmedicine.com/
BörsenkürzelIRON
IPO-datumAug 12, 2020
CEOQuisel (John D)
Führungskräfte von Disc Medicine Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
36.87K
--
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
6.03K
-63499.00%
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Director
Director
--
--
Dr. John D. Quisel, J.D., Ph.D.
Dr. John D. Quisel, J.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Kevin J. Bitterman, Ph.D.
Mr. Kevin J. Bitterman, Ph.D.
Independent Director
Independent Director
--
--
Mr. Mark Chin
Mr. Mark Chin
Independent Director
Independent Director
--
--
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. William White, J.D.
Mr. William White, J.D.
Independent Director
Independent Director
--
--
Dr. William Savage, M.D., Ph.D.
Dr. William Savage, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
36.87K
--
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
6.03K
-63499.00%
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Director
Director
--
--
Dr. John D. Quisel, J.D., Ph.D.
Dr. John D. Quisel, J.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Kevin J. Bitterman, Ph.D.
Mr. Kevin J. Bitterman, Ph.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sat, Jan 31
Aktualisiert: Sat, Jan 31
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
10.43%
Access Industries, Inc.
7.46%
RA Capital Management, LP
5.90%
The Vanguard Group, Inc.
4.67%
BlackRock Institutional Trust Company, N.A.
4.49%
Andere
67.05%
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
10.43%
Access Industries, Inc.
7.46%
RA Capital Management, LP
5.90%
The Vanguard Group, Inc.
4.67%
BlackRock Institutional Trust Company, N.A.
4.49%
Andere
67.05%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
40.95%
Investment Advisor/Hedge Fund
19.54%
Hedge Fund
15.71%
Venture Capital
11.72%
Private Equity
8.55%
Corporation
7.46%
Research Firm
2.13%
Sovereign Wealth Fund
0.90%
Individual Investor
0.43%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
358
37.59M
99.56%
-1.45M
2025Q3
341
35.08M
92.93%
-3.22M
2025Q2
344
37.34M
107.82%
+1.72M
2025Q1
342
37.53M
108.38%
+1.77M
2024Q4
318
30.70M
90.70%
-5.11M
2024Q3
302
32.06M
106.93%
-4.30M
2024Q2
292
32.17M
107.84%
+2.52M
2024Q1
275
26.60M
108.28%
-1.06M
2023Q4
248
24.37M
101.48%
-1.80M
2023Q3
211
23.78M
99.79%
-259.52K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Fidelity Management & Research Company LLC
3.94M
10.43%
+855.03K
+27.73%
Sep 30, 2025
Access Industries, Inc.
2.81M
7.46%
-744.05K
-20.91%
Oct 20, 2025
RA Capital Management, LP
1.58M
4.18%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
1.44M
3.82%
+51.32K
+3.69%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
1.70M
4.49%
-17.33K
-1.01%
Sep 30, 2025
Atlas Venture
1.51M
4.01%
-628.74K
-29.34%
Dec 17, 2025
Frazier Life Sciences Management, L.P.
1.44M
3.81%
-216.30K
-13.07%
Sep 30, 2025
OrbiMed Advisors, LLC
1.42M
3.75%
--
--
Sep 30, 2025
Wellington Management Company, LLP
1.41M
3.74%
-22.01K
-1.54%
Sep 30, 2025
T. Rowe Price Associates, Inc.
1.30M
3.44%
-194.10K
-12.99%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
ALPS Medical Breakthroughs ETF
1.25%
Virtus LifeSci Biotech Clinical Trials ETF
1.11%
JPMorgan Healthcare Leaders ETF
0.92%
State Street SPDR S&P Biotech ETF
0.79%
Direxion Daily S&P Biotech Bull 3X Shares
0.48%
JPMorgan Fundamental Data Science Small Core ETF
0.4%
ProShares Ultra Nasdaq Biotechnology
0.39%
Invesco Nasdaq Biotechnology ETF
0.29%
iShares Health Innovation Active ETF
0.27%
iShares Biotechnology ETF
0.18%
Mehr Anzeigen
ALPS Medical Breakthroughs ETF
Anteil1.25%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil1.11%
JPMorgan Healthcare Leaders ETF
Anteil0.92%
State Street SPDR S&P Biotech ETF
Anteil0.79%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.48%
JPMorgan Fundamental Data Science Small Core ETF
Anteil0.4%
ProShares Ultra Nasdaq Biotechnology
Anteil0.39%
Invesco Nasdaq Biotechnology ETF
Anteil0.29%
iShares Health Innovation Active ETF
Anteil0.27%
iShares Biotechnology ETF
Anteil0.18%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Datum
Ex-Dividendentag
Art
Verhältnis
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
